

XXIX SIMPOSI SOCIETAT CATALANA DE CONTRACEPCIÓ

13 de març de 2025

Nous mètodes d'anticoncepció femenina i de barrera

José Vicente González Navarro

Ginecòlogo, Zaragoza



SUMARIO



Novedades en anticoncepción en España



Novedades en anticoncepción pendiente de llegar a España



Novedades en anticoncepción de barrera


Viejos métodos, nuevas combinaciones

Nuevos métodos anticonceptivos





Novedades en anticoncepción en España



Estetrol




Drovelis®
Estetrol 14,2 mg & DRSP 3 mg

DIU-LNG: 52 mg

5 años

8 años



Levosert ONE®



Novedades en anticoncepción pendientes de llegar a España



21/7 x 13 ciclos

Annovera[®]
EE: 17,4 mg & Nesterona: 103 mg



Progering[®]
Progesterona



PROGESTERONE-RELEASING VAGINAL RING FOR BREASTFEEDING WOMEN		
PVRs do not protect against sexually transmitted infections (STIs), including HIV. If there is a risk of STI/HIV, the correct and consistent use of condoms is recommended. When used correctly and consistently, condoms offer one of the most effective methods of protection against STIs, including HIV. Female condoms are effective and safe, but are not used as widely by national programmes as male condoms.		
CONDITION † recommendations reviewed for the MEC 5th edition, further details after this table	CATEGORY	CLARIFICATIONS/EVIDENCE
PREGNANCY	NA	NA = not applicable Clarification: Use of PVRs is not required. There is no known harm to the woman, the course of her pregnancy, or the fetus if PVRs are accidentally used during pregnancy.
BREASTFEEDING ≥ 4 WEEKS POSTPARTUM†	1	Clarification: The woman must be actively breastfeeding (i.e. at least 4 breastfeeding episodes per day) during PVR use to maintain efficacy. Evidence: No differences were observed between various measures of breastfeeding performance among PVR users compared with users of non-hormonal or progestogen-only (synthetic progesterone) contraceptives during 12 months of observation (3–8). No statistically significant differences in infant weight gain were observed among PVR users compared with women using a non-hormonal or progestogen-only contraceptives (5, 7, 9), and similar patterns of infant weight gain were observed in another study that compared PVR and IUD users (8). One study reported no significant difference in infant health (8).

Criterios médico de elegibilidad en anticoncepción, OMS




90 dias



Injectable mensual



Injectable trimestral



Sayana®
Medroxiprogesterona: 104 mg




- ✧ Vía i.m.
- ✧ Dosis: 150 mg
- ✧ Personal sanitario

VS


- ✧ Vía subcutánea.
- ✧ Dosis: 104 mg
- ✧ Autoadministrado

NUEVOS MÉTODOS DE BARRERA





Usuaris de anticoncepció 15 a 49 anys



Encuesta de Anticoncepción en España 2024

Hábitos de la población femenina en relación al uso de métodos anticonceptivos



SEC 2024*

SOCIETAT CATALANA DE
CONTRA
CEPCIÓ







- ✧ Mayor resistencia
- ✧ Mayor sensibilidad




LELO HEX®



Preservativo vegano

- ✧ Látex natural
- ✧ Sin caseína, talco, parabenos o sustancias de origen animal



Instrucciones de uso

1 Sáquelo de la tarjeta y despléguelo.



2 Descubra la cabeza del pene e introduzca en el condón, apriete y saque aire.



3 No se desenrolle como un condón común, para facilitar su colocación, estire el pene sin erección antes de halar la arandela.



4 Manteniendo la cabeza estirada hale suavemente la arandela hasta la base.




5 Hale hasta que el condón quede liso sacando el aire.

- Use cualquier lubricante después de poner el condón.

SOCIAT CATALANA DE
CONTRA
CEPCIÓ


L'Acadèmia



Femidom®



PATH Women's Condom®





Wondaleaf®



NIH National Library of Medicine
National Center for Biotechnology Information

PubMed®


Avanzado

Ahorrar Correo electrónico



Ensayo controlado aleatorio > Int J ETS SIDA. Febrero 2023;34(2):114-121.
doi: 10.1177/09564624221139899. Publicación electrónica 25 de noviembre de 2022.

**Rendimiento funcional del condón Wondaleaf:
ensayo clínico aleatorizado, cruzado y de no
inferioridad**


Revistas Beksinska ¹, No hlanhla mphili ¹, Jenni Smith ¹




Diafragma Caya®



- ✧ Más fácil de usar
- ✧ Mayor adaptación anatómica



Nonoxinol 9



Phexxi®

Ácido láctico, ácido cítrico y bitartrato de potasio









Caya Gel®: Ácido láctico, lactato sodico, ácido sórbico y celulosa

Contragel®: Ácido láctico, lactato sódico, ácido sórbico y vanilina





Anticoncepción del futuro



Viejos métodos, nuevas combinaciones

Dose-finding study of a 90-day contraceptive vaginal ring releasing estradiol and segesterone acetate

Estradiol & Nesterona

Ensayo clínico de fase 2, multicéntrico, abierto, aleatorizado, para evaluar la inhibición de la ovulación de tres dosificaciones de levonorgestrel (LNG) en un sistema de liberación vaginal (SLV).

Levonorgestrel

Un estudio de búsqueda de dosis para evaluar la función ovárica y el sangrado vaginal en anillos de próxima generación (P06109/MK-8175A/MK-8342B-012)

Estradiol & Nomegestrol

Ensayo clínico de fase 3, aleatorizado, controlado con un fármaco de comparación activo, para estudiar la eficacia anticonceptiva y de seguridad del anillo vaginal MK-8342B (etonogestrel + 17β estradiol)

Estradiol & Etonogestrel

Contraception

Contraception 90 (2014) 565–574

Original research article

A randomized study on pharmacodynamic effects of vaginal rings delivering the progesterone receptor modulator ulipristal acetate: research for a novel estrogen-free, method of contraception ☆☆☆,★☆☆,☆☆☆,☆☆☆☆

YongMei Huang^a, Jeffrey T. Jensen^b, Vivian Brache^c, Leila Cochon^c, Alistair Williams^d,

Contraception 87 (2013) 314–318

Review article

Vaginal ring delivery of selective progesterone receptor modulators for contraception

Jeffrey T. Jensen*

Ac. Ulipristal



Contraception

Contraception 69 (2004) 137–144
Original research article

Two-year performance of a Nestorone®-releasing contraceptive implant: a three-center study of 300 women

Irving Sivin^{a,*}, Horacio Croxatto^b, Luis Bahamondes^c, Vivian Brache^d, Francisco Alvarez^d,
Rebeca Massai^b, Janet Schechter^a, Sirpa Ranta^e, Narender Kumar^a, Esther Wu^a,
Ana Sofia Tejeda^d, Veronica Reyes^b, Elaine Travers^a, Arthur Allen^a, Alfred Moo-Young^a



Contraception

Contraception 74 (2006) 492–497

Original research article

Effects of a single Silastic® contraceptive implant containing nomegestrol acetate (Uniplant) on endometrial morphology and ovarian function for 1 year[☆]

Ione Cristina Barbosa^{*}, Hugo Maia Jr., Elsimar Coutinho, Renata Lopes,
Antonio C.V. Lopes, Cristina Noronha, Adelmo Botto

Maternidade Clémir de Oliveira, Federal University of Bahia, Salvador, Bahia 40055-150, Brazil

Nestorona

Nomegestrol






PCI BPC > Registro de ensayos clínicos de EE. UU. > Ensayo clínico NCT01236768

Sistema de administración transdérmica de anticonceptivos (TCDS), también conocido como brazo con parche AG200-15 (ATI-CL13)

Etinilestradiol & Levonorgestrel



Contraception

Contraception 92 (2015) 289–297

Original research article

A dose-finding, cross-over study to evaluate the effect of a Nestorone®/Estradiol transdermal gel delivery on ovulation suppression in normal ovulating women[☆]

Vivian Brache^{a,*}, Ruth Merkatz^b, Narender Kumar^b, Cristian Jesam^c, Heather Sussman^b, Elena Hoskin^b, Kevin Roberts^b, Mohcine Alami^b, Deshawn Taylor^d, Aidelis Jorge^a, Horacio Croxatto^c, Ellen Lorange^c, Daniel R. Mishell^d, Regine Sitruk-Ware^b

Estradiol & Nestorona

NIH National Library of Medicine
National Center for Biotechnology Information

ClinicalTrials.gov

Encuentra estudios ▾ Conceptos básicos de estudio ▾ Presentar estudios ▾ Datos y API ▾ Política ▾


Píldora que contiene solo drospirenona como medida de emergenciaAnticoncepción

Identificación de ClinicalTrials.gov ⓘ NCT05675644

Patrocinador ⓘ Universidad de Colorado, Denver

Información proporcionada por ⓘ Universidad de Colorado, Denver (Parte responsable)

Drospirenona



NIH National Library of Medicine
National Center for Biotechnology Information

ClinicalTrials.gov

Encuentra estudios ▾ Conceptos básicos de estudio ▾ Presentar estudios ▾ Datos y API ▾ Política ▾

Acetato de medroxiprogesterona de depósito como medicamento de emergenciaAnticoncepción

Identificación de ClinicalTrials.gov ⓘ NCT03395756

Patrocinador ⓘ Universidad del Sur de California

Información proporcionada por ⓘ Brian T. Nguyen, MD MSc, Universidad del Sur de California (Parte responsable)

Última actualización publicada ⓘ 5 de noviembre de 2020

Ac medroxiprogesterona



NIH National Library of Medicine
National Center for Biotechnology Information

ClinicalTrials.gov

Encuentra estudios ▾ Conceptos básicos de estudio ▾ Presentar estudios ▾ Datos y API ▾ Política ▾

Implante de etonogestrel como medida de urgenciaAnticoncepción

Identificación de ClinicalTrials.gov ⓘ NCT05237141



Patrocinador ⓘ Universidad de Colorado, Denver

Información proporcionada por ⓘ Universidad de Colorado, Denver (Parte responsable)

Última actualización publicada ⓘ 20 de abril de 2023

Etonogestrel





PCI BPC > Registro de ensayos clínicos de EE. UU. > Ensayo clínico NCT00967746

Un ensayo exploratorio para explorar la seguridad, la aceptabilidad y el patrón de sangrado vaginal de tres sistemas intrauterinos medicados que liberan etonogestrel (estudio P06060)

Etonogestrel

NIH National Library of Medicine
National Center for Biotechnology Information

ClinicalTrials.gov

Find Studies ▾ Study Basics ▾ Submit Studies ▾ Data and API ▾ Policy ▾ About ▾

ACTIVE, NOT RECRUITING ⓘ

Evaluation of Efficacy, Safety and Tolerability of VeraCept IUD

ClinicalTrials.gov ID ⓘ NCT03633799

Sponsor ⓘ Sebela Women's Health Inc.

Information provided by ⓘ Sebela Pharmaceuticals Inc. (Sebela Women's Health Inc.) (Responsible Party)

ELSEVIER

Contraception
Volume 104, Issue 4, October 2021, Pages 327-336

Original Research Article

Pharmacodynamics and pharmacokinetics of a copper intrauterine contraceptive system releasing ulipristal acetate: A randomized proof-of-concept study


Vivian Brache^{a,†}, Carolina Sales Vieira^{b,†}, Marlana Plagianos^c, Maud Lansiaux^c, Ruth Merkatz^c, Heather Sussman^c, Leila Cochon^a, Ana S Tejada^a, Narender Kumar^c

Ac Ulipristal

► Rev. Obstetricia y Ginecología. Otoño de 2010;3(4):156-162.

Características clínicas del sistema Adiana® para anticoncepción permanente: el primer año de uso comercial

[Seth J. Herbst](#)¹, [Edward G. Evantash](#)²



Adiana®

Good Clinical Practice
NETWORK

REGLAMENTO ▾ LISTA DE CRO ENSAYOS CLÍNICOS ▾

Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a [versión Ingles](#)

ICH GCP > Registro de ensayos clínicos de EE. UU. > Ensayo clínico NCT03067272

Ensayo piloto de oclusión tubárica bilateral para la anticoncepción femenina permanente (BLOC)

5 de mayo de 2023 actualizado



Estudio piloto para la anticoncepción permanente FemBloc

ISSN: 2576-2842

Research Article **Journal of Gynecology & Reproductive Medicine**


FemBloc Non-Surgical Permanent Contraception for Occlusion of the Fallopian Tubes

James H. Liu^{1,2*}, Paul D. Blumenthal³, Paula M. Castano⁴, Scott C. Chudnoff⁵, Lori M. Gawron⁶, Erica B. Johnstone⁶ and Kathy Lee-Sepsick²



FemBloc®









Nuevos métodos anticonceptivos

Métodos “Large Action Inyectables” (LAI)

3 meses < **LAI** < LARC



Dosis más altas



Nuevas sales / esteres








Nuevos vehículos

- Microesferas
- Gelificantes





Nuevos sistemas de administración

- Parches de microagujas



Tecnologías de prevención multipropósito (MTPs)



Tecnologías de prevención multipropósito (MTPs)

The MPT Pipeline by Delivery Method



Product Name	Product Developer	Stage of Development	Indications
Anillo vaginal			
Dapivirine + Pritelivir + Levonorgestrel 3D Printed IVR	Chapel Hill	Early Preclinical	HIV, Pregnancy, HSV-2
Islatravir (EFdA) + Etonogestrel/Ethinyl Estradiol 3D Printed IVR	University of North Carolina, Chapel Hill	Early Preclinical	HIV, Pregnancy
Novel mAb contraceptive + Tenofovir Disoproxil Fumarate (TDF) IVR	Oak Crest Institute of Science, Univ. of North Carolina, Chapel Hill	Early Preclinical	HIV, Pregnancy
90-day Pod-type Etonogestrel/Ethinyl Estradiol/QGriffithsin (EEQ) IVR	Population Council, Oak Crest Institute of Science	Early Preclinical	HIV, Pregnancy
Novel IVR as a Non-Hormonal Contraceptive MPT	Population Council, Queen's University Belfast, Weill Cornell Medical College	Early Preclinical	HIV, Pregnancy, HSV-2, Gonorrhea, Chlamydia, BV
mAb 2C7 + TDF IVR	MassBiologics, Oak Crest Institute of Science, Planet Biotechnology, Inc., University of Massachusetts	Advanced Preclinical	HIV, Gonorrhea
Non-ARV/Non-Hormonal Multi-Purpose Vaginal Ring	Oak Crest Institute of Science	Advanced Preclinical	HIV, Pregnancy, HSV-1, HSV-2, HPV
Dapivirine + Levonorgestrel IVR	Population Council	Phase 1 Clinical Trial	HIV, Pregnancy
Gel vaginal			
Yaso-GEL		Phase 0 Clinical Trial	Pregnancy, HSV-2, Gonorrhea
VivaGel® Vaginal Gel	Starpharma Ltd.	Phase 3 Clinical Trial (US); Registered	HIV, HSV-2, HPV, BV
Implante de disolución rápida			
Griffithsin (GRFT) Fast-Dissolving Insert (FDI)	Population Council	Pre-formulation	HIV, HSV-2, HPV
Non-hormonal Contraceptive MPT Containing Q-Griffithsin (QGRFT)	Population Council	Early Preclinical	HIV, Pregnancy, HSV-2, BV, Chlamydia, Gonorrhea
Tenofovir Alafenamide (TAF) / Elvitegravir Topical Insert	CONRAD	Phase 1 Clinical Trial	HIV, HSV-2
DIU (IUDs)			
Low-profile copper IUD	University of Washington	Early Preclinical	HIV, Pregnancy

The MPT Pipeline by Delivery Method



Product Name	Product Developer	Stage of Development	Indications
Film vaginal			
EFdA-P + Progestin Intravaginal Film	Magee-Women's Research Inst. & Fndn., University of Pittsburgh	Early Preclinical	HIV, Pregnancy
Dapivirine/Levonorgestrel Extended-Release Monthly Film	Magee-Women's Research Inst. & Fndn., University of Pittsburgh	Early Preclinical	HIV, Pregnancy
Implantes			
Cabotegravir Pellet Implant with Levonorgestrel	CONRAD	Early Preclinical	HIV, Pregnancy
Long-acting refillable nanofluidic implant (NanoMPI)- SC	University of Washington Methodist Hospital Research Institute (UW-MHI)	Early Preclinical	HIV, Pregnancy
Inyectable			
Cabotegravir/Levonorgestrel Long-Acting MPT Injectable	CONRAD	Advanced Preclinical	HIV, Pregnancy
Injectable In-situ Forming Implants			
Ultra-Long-Acting MPT In-situ Forming Implant (ISFI)	University of North Carolina, Chapel Hill	Early Preclinical	HIV, Pregnancy
Píldora			
Dual Prevention Pill (DPP)/TELE	Viatrix	Bioequivalence Clinical Study	HIV, Pregnancy






PCI BPC > Registro de ensayos clínicos de EE. UU. > Ensayo clínico NCT01839643

Evaluación de un anillo vaginal con meloxicam sobre el ciclo ovárico en mujeres fértiles


Ovulación



Antic. "Hormonal"

Inhibición LH
Inhibición FSH

**Estrógenos
Gestágenos**





Antic. "AINE"


Alteración maduración ovocitos
Bloqueo ruptura folicular
Inhiben complejo cúmulo ovocito

Antiprostaglandínicos

Inmunokontracepció.-




Vacunas



Inmunización Pasiva

Inmunokontracepció: Vacunas anticonceptivas.



Inmuncontracepción pasiva

 ichgcp.net/clinical-trials-registry/NCT04731818

PCI BPC > Registro de ensayos clínicos de EE. UU. > Ensayo clínico NCT04731818


Un estudio exploratorio de ZB-06 como película anticonceptiva vaginal

31 de marzo de 2023 actualizado por: [KBio Inc](#)


Un estudio exploratorio de fase 1 sobre el mecanismo de acción de ZB-06, una película vaginal que contiene HC4-N, un anticuerpo monoclonal antiespermatozoide.

Anticuerpo Anticonceptivo Humano (HCA) + VRC01 + N6 IVR	No hormonal	intravaginal	Anillo intravaginal (IVR)	HCA Anticuerpos monoclonicos VRC01+N6	MUCOMMUNE LLC
mAb 2C7 + TDF IVR	No anticonceptivos	intravaginal	Anillo intravaginal (IVR)	Anticuerpos monoclonicos Fumarato de tenofovir disoproxilo (TDF)	MassBiologics Instituto de Ciencias Oak Crest Planeta Biotecnología, Inc. Universidad de Massachusetts
Nuevo anticonceptivo mAb + TDF IVR	No hormonal	intravaginal	Anillo intravaginal (IVR)	Anticuerpos monoclonicos Fumarato de tenofovir disoproxilo (TDF)	Instituto de Ciencias Oak Crest Universidad de Carolina del Norte, Chapel Hill



Multipropósito




Anticuerpos monoclonales




Implantes biodegradables



Anticoncepción



Multipropósito




Sistemas microelectroquímicos



INICIO SEC ÁREA DE SOCIOS/AS ÁREA CIENTÍFICA ÁREA DE CONSULTA ÁREA DE FORMACIÓN ÁREA DE PREN

A la búsqueda del microchip anticonceptivo con control remoto

INICIO / SOCIEDAD ESPAÑOLA DE CONTRACEPCIÓN / A LA BÚSQUEDA DEL MICROCHIP ANTICONCEPTIVO CON CONTROL REMOTO



Moltes gràcies